This lecture from the iBioSeminars project is presented by Brian Druker of HHMI and the Oregon Health & Science University Cancer Institute. It describes the lessons learned from the clinical trials of imatinib. This will include examples of where imatinib has or has not worked, analysis of target expression versus activation and a discussion of how the success of imatinib can be translated to other malignancies. The section concludes with what this means for research to control or cure cancer in the coming decades. This video is the last of three, running 22:09 minutes and can be downloaded in QuickTime, MP4, M4V, or PDF formats. It can also be streamed on iTunes or YouTube.
(no comments available yet for this resource)